CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 600 enrolled
Drug / intervention
LUBT010 (proposed ranibizumab biosimilar) +1 moredrug
Likely dose
LUBT010 (proposed ranibizumab biosimilar) 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04690556
NCT04690556Phase 3Completed
CompareCT.gov

A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 With Lucentis® in Patients With Neovascular Age Related Macular Degeneration

Lupin Ltd.·interventional·Posted Dec 30, 2020·Updated Jan 29, 2026

In Brief

A Phase 3 clinical trial evaluating LUBT010 (proposed ranibizumab biosimilar) and Lucentis (ranibizumab) for Neovascular Age-related Macular Degeneration. Completed, enrolled 600 participants across 78 sites in 7 countries.

Detailed Summary

This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-related Macular Degeneration
CountriesBulgaria, Hungary, India, Poland, Russia, Slovakia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedDec 30, 2020
Enrollment StartSep 14, 2020
Primary CompletionMay 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.5 years ago

Interventions

LUBT010 (proposed ranibizumab biosimilar)drug

LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly

Lucentis (ranibizumab)drug

Lucentis® 0.5 mg via intravitreal injection once monthly